| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $59,839 | 2 | 20 |
Sells | $7,548,676 | 8 | 80 |
| Sebelius Kathleen | director | 1 | $50,000 | 0 | $0 | $50,000 |
| Constantino Michael T. | director | 1 | $9,840 | 0 | $0 | $9,840 |
| Parikh Shamik J | Chief Medical Officer | 0 | $0 | 1 | $41,147 | $-41,147 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | 0 | $0 | 1 | $41,147 | $-41,147 |
| Dougan Brady W | director | 0 | $0 | 3 | $3.73M | $-3.73M |
| Niklason Laura E | President, CEO and Director | 0 | $0 | 3 | $3.73M | $-3.73M |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Over the last 12 months, insiders at Humacyte, Inc. have bought $59,839 and sold $7.55M worth of Humacyte, Inc. stock.
On average, over the past 5 years, insiders at Humacyte, Inc. have bought $9.5M and sold $41.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sebelius Kathleen (director) — $50,000. Constantino Michael T. (director) — $9,840.
The last purchase of 56,818 shares for transaction amount of $50,000 was made by Sebelius Kathleen (director) on 2026‑05‑19.
| 2026-05-19 | Sebelius Kathleen | director | 56,818 0.0361% | $0.88 | $50,000 | +53.58% | ||
| 2026-05-18 | Sale | Parikh Shamik J | Chief Medical Officer | 45,887 0.0273% | $0.90 | $41,147 | +37.47% | |
| 2026-05-18 | Sale | Sander Dale A. | CFO and Chief Corp. Dev. Off | 45,887 0.0273% | $0.90 | $41,147 | +37.47% | |
| 2026-05-18 | Constantino Michael T. | director | 11,000 0.0065% | $0.89 | $9,840 | +37.47% | ||
| 2025-08-20 | Sale | Niklason Laura E | President, CEO and Director | 591,685 0.3621% | $1.58 | $934,862 | -29.45% | |
| 2025-08-20 | Sale | Dougan Brady W | director | 591,685 0.3621% | $1.58 | $934,862 | -29.45% | |
| 2025-08-19 | Sale | Niklason Laura E | President, CEO and Director | 1.1M 0.7098% | $1.63 | $1.79M | -28.13% | |
| 2025-08-19 | Sale | Dougan Brady W | director | 1.1M 0.7098% | $1.63 | $1.79M | -28.13% | |
| 2025-08-18 | Sale | Niklason Laura E | President, CEO and Director | 549,360 0.3527% | $1.83 | $1.01M | -36.11% | |
| 2025-08-18 | Sale | Dougan Brady W | director | 549,360 0.3527% | $1.83 | $1.01M | -36.11% | |
| 2025-04-14 | Scheessele William John | Chief Commercial Officer | 6,493 0.0051% | $1.54 | $9,999 | -2.01% | ||
| 2025-04-10 | Sander Dale A. | CFO and Chief Corp. Deve. Off. | 20,000 0.0157% | $1.53 | $30,600 | -7.01% | ||
| 2025-04-10 | Parikh Shamik J | Chief Medical Officer | 7,500 0.0059% | $1.55 | $11,625 | -7.01% | ||
| 2025-04-08 | Sebelius Kathleen | director | 50,000 0.0338% | $1.32 | $66,000 | +27.83% | ||
| 2025-04-08 | Green Charles Bruce | director | 6,000 0.004% | $1.29 | $7,740 | +27.83% | ||
| 2025-04-07 | Constantino Michael T. | director | 16,000 0.0103% | $1.26 | $20,160 | +16.67% | ||
| 2024-12-04 | Constantino Michael T. | director | 4,600 0.0036% | $4.39 | $20,181 | -49.66% | ||
| 2024-11-20 | Sale | Niklason Laura E | President, CEO and Director | 261,369 0.2032% | $4.40 | $1.15M | -47.73% | |
| 2024-11-20 | Sale | Dougan Brady W | director | 261,369 0.2032% | $4.40 | $1.15M | -47.73% | |
| 2024-11-19 | Sale | Niklason Laura E | President, CEO and Director | 427,459 0.3354% | $4.34 | $1.86M | -47.74% |
| Parikh Shamik J | Chief Medical Officer | 272713 0.1623% | $368,162.55 | 1 | 1 | <0.0001% |
| Sander Dale A. | CFO and Chief Corp. Dev. Off | 267213 0.1591% | $360,737.55 | 3 | 2 | <0.0001% |
| Sebelius Kathleen | director | 148025 0.0881% | $199,833.75 | 2 | 1 | +27.83% |
| Constantino Michael T. | director | 43950 0.0262% | $59,332.50 | 6 | 0 | <0.0001% |
| Dougan Brady W | director | 0 0% | $0 | 7 | 27 | <0.0001% |
| Niklason Laura E | President, CEO and Director | 0 0% | $0 | 7 | 27 | <0.0001% |
| Ayabudge LLC | 10 percent owner | 8191140 4.8757% | $11.06M | 1 | 10 | <0.0001% |
| Binder Gordon M | director | 160000 0.0952% | $216,000.00 | 3 | 0 | <0.0001% |
| Scheessele William John | Chief Commercial Officer | 22018 0.0131% | $29,724.30 | 3 | 0 | <0.0001% |
| Green Charles Bruce | director | 8400 0.005% | $11,340.00 | 1 | 0 | +27.83% |
| Wallace Max N. | director | 4015 0.0024% | $5,420.25 | 1 | 0 | <0.0001% |
| Prichard Heather Ledbetter | Chief Operating Officer | 0 0% | $0 | 0 | 4 |
$9,456,760 | 65 | 2.69% | $232.7M | |
$24,442,471 | 44 | -29.96% | $239.18M | |
$130,095 | 43 | 45.19% | $238.17M | |
$168,352,523 | 35 | 13.58% | $216.91M | |
Humacyte, Inc. (HUMA) | $47,438,336 | 33 | -21.38% | $226.8M |
$74,231,875 | 30 | 40.62% | $247.29M | |
$295,092,700 | 21 | -0.27% | $230.79M | |
$38,821,584 | 20 | -2.17% | $248.53M | |
$1,037,470 | 13 | 78.00% | $207.49M | |
$446,126 | 12 | -6.92% | $233.53M | |
$2,762,881 | 8 | -10.76% | $215.21M | |
$119,804,612 | 8 | -17.22% | $219.4M | |
$603,645 | 8 | 57.40% | $229.39M | |
$8,293,950 | 7 | 5.14% | $248.65M | |
$4,745,999 | 5 | -4.91% | $221.07M | |
$15,551,156 | 3 | 98.82% | $219.79M | |
$193,101 | 3 | -25.20% | $207.71M | |
$4,888,000 | 3 | -20.50% | $219M | |
$63,731 | 1 | -19.50% | $220.25M |
| Increased Positions | 83 | +60.58% | 13M | +28.06% |
| Decreased Positions | 51 | -37.23% | 3M | -6.49% |
| New Positions | 27 | New | 2M | New |
| Sold Out Positions | 16 | Sold Out | 630,831 | Sold Out |
| Total Postitions | 169 | +23.36% | 56M | +21.56% |
| Blackrock, Inc. | $9,654.00 | 5.13% | 9.9M | -43,653 | -0.44% | 2025-09-30 |
| Vanguard Group Inc | $7,332.00 | 3.9% | 7.52M | +520,431 | +7.43% | 2025-09-30 |
| Geode Capital Management, Llc | $3,019.00 | 1.6% | 3.1M | +147,708 | +5.01% | 2025-09-30 |
| State Street Corp | $2,348.00 | 1.25% | 2.41M | -2M | -45.16% | 2025-09-30 |
| Morgan Stanley | $2,044.00 | 1.09% | 2.1M | +720,158 | +52.31% | 2025-09-30 |
| Ubs Group Ag | $1,952.00 | 1.04% | 2M | -443,136 | -18.12% | 2025-09-30 |
| Woodline Partners Lp | $1,952.00 | 1.04% | 2M | +680 | +0.03% | 2025-09-30 |
| Two Sigma Investments, Lp | $1,332.00 | 0.71% | 1.37M | -170,797 | -11.11% | 2025-09-30 |
| Millennium Management Llc | $1,118.00 | 0.59% | 1.15M | -1M | -55.08% | 2025-09-30 |
| Susquehanna International Group, Llp | $1,114.00 | 0.59% | 1.14M | -273,500 | -19.31% | 2025-09-30 |